EMEA-001830-PIP01-15-M02
Key facts
| Invented name |
|
| Active substance |
Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0188/2020
|
| PIP number |
EMEA-001830-PIP01-15-M02
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Prevention of influenza infection
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Seqirus S.r.l.
Tel. +39 0577096405; +39 0577096401 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001830-PIP01-15-M02
|
| Compliance opinion date |
16/12/2022
|
| Compliance outcome |
positive
|